Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 1 , Pages 67-71, January 2009

Outcomes for intermediate risk prostate cancer: Are there advantages for surgery, external radiation, or brachytherapy?

  • Eric A. Klein, M.D.

      Affiliations

    • Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    • Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-216-444-5591; fax: +1-216-445-3532
    • ,
  • Jay Ciezki, M.D.

      Affiliations

    • Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
    • Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
    • ,
  • Patrick A. Kupelian, M.D.

      Affiliations

    • M.D. Anderson Cancer Center Orlando, Orlando, FL 32806, USA
    • ,
  • Arul Mahadevan, M.D.

      Affiliations

    • Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
    • Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA

Abstract 

The treatment of localized prostate cancer remains controversial because of the lack of conclusive well-controlled or randomized studies comparing outcome of various forms of radiotherapy (RT) to radical prostatectomy (RP). We review recent results from an institutional database and prospective quality of life study comparing cancer-related and quality of live (QOL) outcomes among different treatment modalities for intermediate risk prostate cancer. The results suggest similar short-term survival but domain-specific effects on QOL after treatment with radical prostatectomy, brachytherapy, or external beam radiotherapy.

Keywords: Prostate cancer, Radical prostatectomy, External radiation, Brachytherapy, Quality of life

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1078-1439(08)00075-6

doi:10.1016/j.urolonc.2008.04.001

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 1 , Pages 67-71, January 2009

Article Tools

* Image Usage & Resolution